Endometrial Cancer

>

Latest News

Puxitatug samrotecan was well tolerated in patients with advanced or metastatic endometrial cancer.
Puxitatug Samrotecan Exhibits Efficacy in Advanced/Metastatic EC

March 16th 2025

Puxitatug samrotecan was well tolerated in patients with advanced or metastatic endometrial cancer.

A slightly higher complete response rate was observed with the metformin regimen vs with the levonorgestrel-releasing IUD alone in endometrial cancer.
Metformin Plus IUD Well-Tolerated in EIN/Endometrial Cancer

March 16th 2025

No deaths or significant adverse effects were reported in the screened population among those who received hysteroscopic resection for endometrial cancer.
Hysteroscopic Resection Safely Preserves Fertility in Endometrial Cancer

March 16th 2025

Cadonilimab plus lenvatinib appeared to have a manageable safety profile in a phase 2 trial.
Cadonilimab Combo Shows Encouraging Activity in Advanced Endometrial Cancer

March 15th 2025

Adding maintenance olaparib to durvalumab/chemotherapy in pMMR endometrial cancer improved PFS among those with detectable ctDNA at baseline.
Olaparib Combo Enhances PFS Across pMMR Endometrial Cancer Subgroups

March 15th 2025

More News